Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk further slashes prices of Ozempic, Wegovy in India to better compete as generics enter
06:50am, Tuesday, 31'st Mar 2026
Danish drugmaker Novo Nordisk on Tuesday further slashed the price of its popular diabetes and weight-loss drugs Ozempic and Wegovy by as much as 36% and 48% to better
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
10:00am, Monday, 30'th Mar 2026
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novo Nordisk: Why I Still Find It An Interesting Opportunity
08:00am, Monday, 30'th Mar 2026
Novo Nordisk has experienced a sharp 28% YTD and 53% 12-month decline, creating a potentially attractive entry point. Despite macro uncertainty and weakening obesity drug demand, NVO trades at a multi
Novo Nordisk A/S - share repurchase programme
07:49am, Monday, 30'th Mar 2026
Bagsværd, Denmark, 30 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Coun
Novo Nordisk: A Strong Contender in the Pharmaceutical Arena
07:00pm, Friday, 27'th Mar 2026
Explore the exciting world of Novo Nordisk (NVO 1.07%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market tre
Novo Nordisk's Awiqli Gets FDA Approval for Type II Diabetes
01:11pm, Friday, 27'th Mar 2026
NVO secures FDA nod for Awiqli, a once-weekly basal insulin for type II diabetes, strengthening its portfolio and showing strong efficacy in studies.
Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy?
11:00am, Friday, 27'th Mar 2026
One of these companies' lineup and pipeline within weight management and outside look much stronger. Valuation does not tip the scale in the other's favor.
Novo Nordisk: A Comeback Story In The World's Fastest-Growing Drug Market
06:48am, Friday, 27'th Mar 2026
Novo Nordisk is positioned as a durable No. 2 in the obesity drug market, not a loser to Eli Lilly. NVO is expanding manufacturing, advancing next-generation therapies like CagriSema, and leveraging p
Articles of Association for Novo Nordisk A/S 2026
06:23am, Friday, 27'th Mar 2026
500 - Internal server error. Server Error 500 - Internal server error.
US FDA approves Novo's insulin injection for type 2 diabetes
07:54pm, Thursday, 26'th Mar 2026
The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk 's insulin injection, Awiqli, to improve blood sugar levels in adults living with type 2 diabetes
Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
07:36pm, Thursday, 26'th Mar 2026
FDA has approved Awiqli® injection 700 units/mL, the first and only once-weekly, long-acting basal insulin as an adjunct to diet and exercise to improve ..
Novo Nordisk A/S (NOVO:CA) Shareholder/Analyst Call Transcript
05:05pm, Thursday, 26'th Mar 2026
Novo Nordisk A/S (NOVO:CA) Shareholder/Analyst Call Transcript
What's Happening With Novo Nordisk Stock Today?
01:47pm, Thursday, 26'th Mar 2026
Novo Nordisk A/S (NYSE: NVO) shares are moving higher on Thursday. Hims and Hers Health Inc (NYSE: HIMS) announced it will begin offering several of the Novo's FDA‑approved GLP‑1 medications, incl
Resolutions from the Annual General Meeting of Novo Nordisk A/S
11:15am, Thursday, 26'th Mar 2026
Bagsværd, Denmark, 26 March 2026 – Today, Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Lars Rebien Sørensen, chair of the Board of Directors, stated: “2025 w
Novo Nordisk appoints Mars CEO as board observer
11:11am, Thursday, 26'th Mar 2026
Novo Nordisk on Thursday elected Poul Weihrauch, CEO of family-owned U.S. candy and pet food giant Mars, as observer to its board, as the drugmaker seeks to strengthen its position in the highly
